Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vortioxetine - Lundbeck A/S

Drug Profile

Vortioxetine - Lundbeck A/S

Alternative Names: Brintellix; LU-AA21004; LuAA 21004; Trintellix; vortioxetine-hydrobromide

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Seoul National University Hospital; Takeda; University of Chicago
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfides
  • Mechanism of Action Serotonin 1 receptor agonists; Serotonin 1A receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Anxiety disorders; Binge-eating disorder; Bipolar depression
  • Discontinued Attention-deficit hyperactivity disorder; Generalised anxiety disorder

Most Recent Events

  • 24 Sep 2019 Ministry of Health, Labour and Welfare (MHLW) approves NDA application for Trintellix®(vortioxetine) in Major Depressive Disorder
  • 28 Aug 2019 Lundbeck A/S completes a phase II trial for Major depressive disorder (Recurrent) in Estonia, Bulgaria and Latvia (NCT03766867) (EudraCT 2018-000992-34)
  • 22 Jul 2019 Lundbeck completes a phase I trial in Major depressive disorders (In volunteers) in United Kingdom (Sublingual) (NCT03884491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top